Searched for
SEMAGLUTIDE PATENT EXPIRY
Wegovy maker Novo Nordisk faces investor pressure to find growth beyond weight-loss drugsFacing increased scrutiny, Novo Nordisk must clarify its future strategy outside of its leading weight-loss drug. Investors are advocating ...- Sandoz bets big on biosimilars, aims to double group sales by 2035Sandoz plans to more than double annual net sales by 2035, with biosimilars leading growth. The company will expand its biosimilar portfoli...
- How PGIM India's Rs 112 crore Healthcare Fund picks CDMO stocks to generate alphaPGIM India Healthcare Fund generated a 22% return over the past year by over-allocating to high-growth segments like CDMO, specialty pharma...
- Cipla in no hurry to launch semaglutide as Yurpeak gains tractionCipla is focusing on its tirzepatide brand Yurpeak in India's obesity market. Yurpeak has become the second largest GLP-1 product since its...
- Dr Reddy's shares slide 7% after delay in semaglutide supplies over quality concernsDr Reddy's shares fell sharply on Thursday after the company delayed commercial supplies of its semaglutide product due to a quality issue ...
- Dr Reddy's flags quality issue in semaglutide batches, delays commercial suppliesDr Reddy's Laboratories has announced a setback in the distribution of their semaglutide products attributed to out-of-specification batche...
- Wegovy, Ozempic regain weight as Indian generics fall behindNovo Nordisk's weight-loss drugs are regaining market share from Indian generics. Innovator brands show steady month-on-month sales growth,...
- Semaglutide API price plunges amid GLP-1 rushGlobal demand for weight-loss drugs Ozempic and Wegovy has caused semaglutide prices to drop significantly. Manufacturing has expanded rapi...
- Dr Reddy's gets nod to roll out generic oral semaglutide drug"The formulation was clinically evaluated in a head-to-head comparative study conducted in India, which established the non-inferiority to ...
- Novo Nordisk’s weight-loss drug patent loss sparks a ‘gold rush’ for generic drugmakersIndia's weight-loss drug market is seeing a major shift. Generic versions of Novo Nordisk's semaglutide are now available at lower prices. ...
- Novo Nordisk plans to cut price of Ozempic as generics hit marketNovo Nordisk is set to lower the price of its popular weight loss and diabetes drug, Ozempic. This move comes after several Indian drugmake...
- Dr. Reddy’s Lab launches India’s first DCGI-approved Semaglutide injection for Type 2 DiabetesDr. Reddy's Laboratories has launched Obeda, a generic semaglutide injection for Type 2 diabetes, becoming the first Indian company to rece...
- Abbott signs pact with Novo Nordisk to offer semaglutideSemaglutide, sold by Novo Nordisk under brands such as Ozempic and Wegovy, goes off patent on March 21 in India. A raft of Indian generic d...
- Zydus plans launch of semaglutide generic in reusable pen formZydus Lifesciences is set to launch a generic version of the weight-loss injection semaglutide next month. The drug will be available under...
- Sun Pharma gets DCGI nod to launch generic semaglutide for weight managementSun Pharma has gained the green light from the DCGI for its much-anticipated generic version of semaglutide injection, targeting chronic we...
- Sun Pharma gets DCGI nod for Wegovy-like weight loss drug, launch after Novo Nordisk's patent expirySun Pharma has received DCGI approval to launch Noveltreat, a generic semaglutide injection for chronic weight management in India. This GL...
- HC seeks Novo Nordisk's reply on Natco plea to revoke patentThe Delhi High Court has asked Novo Nordisk to explain why its patent for the diabetes and weight loss drug semaglutide should not be cance...
- Delhi HC allows Dr. Reddy’s to export weight-loss drug semaglutide, calls Novo Nordisk’s case ‘weak’The Delhi High Court declined to stay a single-judge order allowing Dr. Reddy's to export its semaglutide, observing Novo Nordisk's appeal ...
- Delhi HC allows Sun Pharma to manufacture, export its own weight loss drugThe Delhi High Court has allowed Sun Pharma to manufacture and export its version of semaglutide, the diabetes and anti-obesity drug made b...
- HC lets Dr Reddy's Laboratories export Semaglutide, blocks India sales till March '26The Delhi High Court has permitted Dr Reddy's Laboratories to produce and export its version of the diabetes and anti-obesity drug semaglut...
Load More
